MUMBAI — Panacea Biotec announced March 3 that it has signed an advance market agreement with the government of India to manufacture Pandyflu, the company's H1N1 flu vaccine.
The company has set up a manufacturing unit for the vaccine on its 75-acre campus at Lalru, Punjab. It will have an annual capacity of 45 million doses, it said in a statement.
The firm also said it expects the vaccine to be available by April for emergency use, it added.
It is expected that Phase I studies would be completed by March to be followed by Phase II/III studies in adult and pediatric population.
Panacea Biotec is the second largest vaccine producer in India.